Beclometasone Dipropionate/Formoterol
- 1 January 2006
- journal article
- Published by Springer Nature in Drugs
- Vol. 66 (11) , 1475-1483
- https://doi.org/10.2165/00003495-200666110-00005
Abstract
▴ A hydrofluoroalkane (HFA)-propelled pressurised metered-dose inhaler (pMDI) has been developed (using Modulite® technology) for a new fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/formoterol) 100μg/6μg. Each actuation of the BDP/formoterol HFA pMDI 100μg/6μg delivers 86.4μg of BDP and 5μg of formoterol. ▴ BDP/formoterol HFA pMDI was associated with significantly higher morning peak expiratory flow (PEF) values than BDP administered alone via a chlorofluorocarbon (CFC) pMDI (including when BDP was administered at a higher dosage) in well designed trials in adults with mild to moderate or moderate to severe asthma. ▴ In terms of morning PEF values, BDP/formoterol HFA pMDI was noninferior to BDP plus formoterol administered via separate inhalers in well designed trials in adults with moderate to severe asthma. ▴ BDP/formoterol HFA pMDI was noninferior to fixed-combination budesonide/formoterol (the daily dosage of BDP was half that of budesonide) in terms of lung function, asthma symptoms and use of rescue medications in adults with moderate to severe asthma. BDP/formoterol HFA pMDI was also noninferior to, and had a faster onset of bronchodilation than, fixed-combination fluticasone propionate/salmeterol. ▴ BDP/formoterol 200μg/12μg per day or 400μg/ 24μg per day administered by the HFA pMDI was generally well tolerated. Moreover, a single high dose of BDP/formoterol (1000μg/60μg) was generally well tolerated in patients with asthma.Keywords
This publication has 21 references indexed in Scilit:
- Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technologyPulmonary Pharmacology & Therapeutics, 2007
- Clinical practice guidelines: Medical follow-up of patients with asthma—Adults and adolescentsRespiratory Medicine, 2005
- Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmaticsAllergy, 2005
- Pharmacokinetic and Pharmacodynamic Properties of Inhaled Beclometasone Dipropionate Delivered Via Hydrofluoroalkane-Containing DevicesClinical Pharmacokinetics, 2005
- Designing Corticosteroid Drugs for Pulmonary SelectivityProceedings of the American Thoracic Society, 2004
- Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthmaPulmonary Pharmacology & Therapeutics, 2003
- Introduction Modulite®: simplifying the changeoverRespiratory Medicine, 2002
- Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in manBritish Journal of Clinical Pharmacology, 2001
- Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle CellsJournal of Biological Chemistry, 1999
- Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potencyEuropean Respiratory Journal, 1997